Drug Type Fusion protein |
Synonyms EGFRFc/HER3Fc heterodimer, EGFRFcHER3Fc, EGFRHER3 ligand trap + [1] |
Target |
Mechanism EGF inhibitors(Epidermal growth factor inhibitors), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Enosi Life Sciences Corp.Startup |
Active Organization Enosi Life Sciences Corp.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | US | Enosi Life Sciences Corp.Startup | - |
Neoplasms | Preclinical | US | Enosi Life Sciences Corp.Startup | - |